Currently more than 1,200 surgeons have been trained on BrainPath from over 250 institutions across the U.S. More than 10,000 procedures have been successfully performed.

Image of access to tumor using BrainPath

Image of access to ICH using BrainPath


The BrainPath is abnormality agnostic— it is all about access. The BrainPath technology does not apply itself by abnormality type, but rather where the abnormality is located. The device provides a pathway to deep locations within the brain.

The difference from a surgical standpoint is that surgeons using BrainPath enter the brain through the sulci, the natural folds of the brain, to displace the critical structures in the white matter to reach the abnormality, thereby reducing the potential for tissue damage. This can set BrainPath apart in the field of brain surgery. Techniques with other existing tools are “trans-gyral” and require surgeons to intentionally cut through the white matter.

While existing minimally invasive approaches also use small openings, surgeons using the BrainPath are not required to cut through the brain’s white matter — tissue responsible for any number of cognitive and functional responses — to reach the target abnormality. BrainPath eases through white matter by displacing tissues like a ship’s hull displaced water. When the surgeon removes the BrainPath tool, the brain tissue can return to its previous position.

There is no other technology on the market that allows this type of minimally disruptive access through the brain – moving brain surgery in a direction much like when knee surgery moved from open surgery to arthroscopic. Today, the trauma and lengthy recovery of open knee surgery is obsolete. Other procedures deemed “minimally invasive” either risk causing trauma to the white matter of the brain during the surgery or utilize tools that emit heat upon resection of the abnormality.

The BrainPath provides minimally disruptive access to the brain abnormality by navigating through the delicate folds and fibers of the brain (see image to right). The two-piece system consists of a clear plastic sheath around a smooth, cylindrical tool with a specially designed tip. The BrainPath enters the brain through an opening smaller than a dime, allowing the surgeon to then navigate through the brain’s natural folds and fiber tracts, carefully displacing brain tissue. Once at the location of the abnormality, the surgeon removes the cylinder from the sheath, leaving the sheath in place to create a portal or narrow corridor through which the surgeon operates.

Additional FDA clearance was granted for BrainPath in July 2015 for design modifications and revised intended use. Revised intended use includes subcortical access to diseases such as primary/secondary brain tumors, vascular abnormalities/malformations, and intraventricular tumors/cysts.

BrainPath Products Page View BrainPath Brochure


The new integrated surgical approach that includes BrainPath is the focus of a growing number of professional neurosurgical organizations and national and international patient advocacy organizations. The approach is also gaining clinical credibility with increasing published evidence and data presentations, including:

100 peer-review publications and abstracts
25 presentations at national and international neurosurgical conferences

Most recently, multi-center clinical results declared as “statistically significant” were granted a national podium presentation at the American Academy of Neurological Surgeons (AANS) and the International Stroke Conference (ISC). The pilot data was built around a standardized surgical approach that includes using BrainPath.

Each of these venues validates the clinical evidence of the approach and outcomes that have directly impacted the growing adoption of technologies used in the approach. Added interest and growing attendance has also been seen in training courses held throughout the year on the approach using BrainPath. Currently, more than 1200 neurosurgeons have been trained using the BrainPath technology and more than 125 hospitals use the technology regularly and are designated BrainPath Centers.

View Clinical Evidence


Approximately 120,000 hemorrhagic strokes occur each year in the United States. This accounts for 10-15 percent of all stroke cases. Unfortunately, almost 80 percent of patients are left physically disabled after their stroke episode.

For intracerebral hemorrhages or hemorrhagic stroke in particular, surgeons often take a watch-and-wait approach and were not being called to administer immediate treatment because it was deemed surgery would be a greater risk to the patient with little clinical benefit. However, study results for a sample of patients presented at the recent International Stroke Conference concluded that using BrainPath resulted in better outcomes for patients.

Hemorrhagic stroke is considered the deadliest class of stroke with an early mortality rate of 32-50 percent. The results of a multi-center study on the safety and efficacy of hematoma evacuation using a trans-sulcal surgical approach with BrainPath showed “statistically significant” improvement in patients’ neurological state associated with early intervention. This improvement was reported in 35 patients at 10 centers with 89 percent clot evacuation, as well as no new deficits or mortalities. The results were cited as a breakthrough in hemorrhagic stroke by the National Stroke Association.

No matter where the tumor, cyst or ICH is located in the brain’s white matter, chances are we can now access and remove it with the goal of greatly improving clinical and functional outcomes as measured by the standards hospitals now look at critically – reduced length of stay, improved functional recovery, and faster recovery. Neurosurgeons can now consider BrainPath a true minimally invasive option for a wide group of patients who had no surgical options before.

1, 2, 3Adeoye O, Broderick JP. Advances in the management of intracerebral haemorrhage. Nat. Rev. Neurol. 2010;6:593-602.  doi: 10.1038/nrneurol.2010.146.
4Van Asch CJJ, Luitse MJA, Rinkel GJE, van der Tweel I, Algra A, Klijn CJM.  Incidence, case fatality, and functional outcome of intracerebral hemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis.  Lancet Neurology.  2010; 9(2):167-176.  doi: 10.1016/S1474-4422(09)70340-0.
5Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.  doi: 10.1161/CIR.0000000000000152. 

Pre- and Post-Op Images: ICH Evacuation Using BrainPath for Access

Related News Stories for ICH

Brainpath sugery patient in the news
Hemorrhagic Advances in StrokeSmart News
strokesmart image 3



The BrainPath provides access to address primary and secondary brain tumors. One of the biggest challenges of traditional white matter surgery is access – how to reach brain tumors that are difficult to get to or located deep in the brain. In a clinical paper authored by MD Anderson, they identified the long-standing problem of traditional subcortical surgery: Subcortical Injury Is an Independent Predictor of Worsening Neurological Deficits Following Awake Craniotomy Procedures. This paper indicates a strong need for a solution like BrainPath in the marketplace.

Pre- and Post-Op Images: Tumor Removal Using BrainPath for Access


Collected clinical data of BrainPath procedures demonstrates the possibility that BrainPath may be used in functional neurosurgery, trauma and anywhere access is a key challenge to treatment of brain abnormalities in what is a very complex surgical environment.

Click HERE to Access Clinical Data


BrainPath Center References

BrainPath Center References

The BrainPath technology is currently being used in more than 125 hospitals, with over 1200 surgeons currently course trained. The technology is being used in large academic centers, medium-sized and small rural hospitals, indicating an across-the-board desire to find a solution to an unmet need. Among those institutions using BrainPath as a standardized surgical approach include:

Facility Location Region
Aurora Neuroscience Innovation Institute Milwaukee, WI Midwest
Cleveland Clinic Foundation Cleveland, OH Midwest
Indiana University Health Indianapolis, IN Midwest
St. Louis University St. Louis, MO Midwest
Washington University St. Louis, MO Midwest
Brigham & Women’s Hospital Boston, MA North East
University of Pittsburgh Pittsburgh, PA North East
Duke University Durham, NC South
Emory Healthcare Atlanta, GA South
Houston Methodist Hospital Houston, TX South
Oklahoma University Oklahoma City, OK South
Sentara Norfolk General Norfolk, VA South
UAMS (Arkansas) Little Rock, AR South
University of North Carolina Chapel Hill, NC South
Abrazo Community Health Network Phoenix, AZ West
Cedars Sinai Medical Center Los Angeles, CA West
Oregon Health – Science University Portland, OR West
Sutter Eden Medical Center Castro Valley, CA West
UC Irvine Medical Center Orange, CA West


Click below to view video of surgical procedures using BrainPath.

BrainPath Videos


The Subcortical Surgery Group (SSG) is a group of neurosurgeons who formed a user group to support the awareness and advancement of this technique and other advanced technologies. The group, registered as a 501(c)(6), was formed to help doctors learn and become trained on the surgical approach, share experiences, and help patients find a surgeon in their area who is trained using the BrainPath integrated surgical approach.

The SSG is led by a Board and Executive Committee of 10 neurosurgeons. All are trained in using BrainPath and routinely perform BrainPath procedures. The SSG board is comprised of:

SSG Board of Directors & Executive Committee

Julian Bailes, MD
President & Chairman, SSG
Chairman, Department of Neurosurgery
NorthShore University HealthSystem
Surgical Director, NorthShore Neurological Institute

Kaisorn Chaichana, MD, FACS
Associate Professor of Neurosurgery, Neuroscience, Oncology, & Otolaryngology
Mayo Clinic

Sunit Das, MD, PhD
Scientist in the Keenan Research Centre for Biomedical Science
Associate Professor, Department of Surgery
University of Toronto

J.D. Day, MD
Chairman, Department of Neurosurgery
University of Arkansas for Medical Sciences

Gary Gallia, MD, PhD
Associate Professor of Neurosurgery & Oncology
Johns Hopkins University School of Medicine

Nicolas Kon Kam King, FRCSEd(SN), PhD
Consultant, Department of Neurosurgery
National Neuroscience Institute
Assistant Professor
Duke-NUS Medical School

Mohamed Labib, MD
Barrow Neurological Institute

Zachary Litvack, MD
Swedish Brain and Spine Specialists

Gustavo Pradilla, MD
Assistant Professor of Neurosurgery
Emory University School of Medicine
Chief of Neurosurgery Service
Marcus Stroke & Neuroscience Center at Grady Health System

Rohan Ramakrishna, MD
Weill Cornell Brain and Spine Center

Justin Singer, MD
Director of Vascular Neurosurgery Program
Spectrum Health

Ronald Young II, MD
Delray Medical Center

Brad Zacharia, MD
Assistant Professor of Neurosurgery
Co-Director, Neuro Oncology Program
Director, Brain Tumor and Skull Base Surgery
Penn State Health

Gabriel Zada, MD
Associate Clinical Professor of Neurosurgery
Keck Medicine of USC

Lloyd Zucker, MD, FAANS
Chief of Neurosurgery, Delray Medical Center
CEO, Florida Neuroscience Institute
Partner, Brain & Spine Center South Florida

Go to SSG Website


The new health care model demands clinical and economic value and in surgical procedures. The BrainPath Approach course teaches a systems approach to trans-sulcal subcortical surgery in the white matter space integrating six technologies (image interpretation & trajectory planning, navigation, optics, access & cannulation, resection, and targeted therapy/neoadjuvant) for minimally invasive neurosurgery performed through small corridors. Surgeons attending the course will be introduced to each of these technologies – as well as provided opportunities for hands-on lab work using the technologies and didactics – for the purpose of creating a template or guide for selecting the surgical approach and the appropriate technology required to address lesions in a targeted manner.

View BrainPath Courses